TMCnet News
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences ConferenceSAN DIEGO --(Business Wire)-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City. 2014 Wedbush Securities Life Sciences Conference Presentation Details Date: Tusday, August 12, 2014 Time: 3:05pm Eastern Time Location: Azekka room @ Le Parker Meridien Webcast: http://wsw.com/webcast/wedbush28/ljpc/ About La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. LJPC-501, the Company's lead product candidate, is a natural peptide for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS (News - Alert)-100, the Company's second product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-401, the Company's third product candidate, is a natural peptide for the potential treatment of iron overload. For more information on the Company, please visit http://www.ljpc.com. |
